サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1439282

心臓バイオマーカー検査 - 世界市場の考察、競合情勢、市場予測（2030年）

Cardiac Biomarkers Testing Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日
発行
DelveInsight
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
心臓バイオマーカー検査 - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 2024年02月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の心臓バイオマーカー検査の市場規模は、2023年に35億米ドル、2030年までに54億8,000万米ドルに達し、2024年～2030年の予測期間にCAGRで7.77％の成長が見込まれます。心血管疾患の有病率の増加、疾患の早期診断ニーズの高まり、老年人口の増加、新たな臨床関連心臓バイオマーカーの同定における研究の進行などの要因が、心臓バイオマーカー検査市場の成長を積極的に刺激しています。

心臓バイオマーカー検査の市場力学

世界保健機関（WHO）（2023）が提供したデータによると、心血管疾患（CVD）は世界全体の主な死因であり、毎年推定1,790万人の命を奪っています。CVDには、心筋梗塞、うっ血性心不全、急性冠症候群などがあります。さらに、WHOの同じデータでは、CVDによる死亡の5人に4人超が、脳卒中と心臓発作を主な原因として挙げており、これらの死亡の3分の1は70歳未満で早期に発生するとしています。また、CVDによる死亡の4分の3超が低中所得国で起こっているとしています。

欧州心臓病学会（ESC）（2023）のデータによると、毎年、欧州では心血管疾患（CVD）が390万人の死因となっており、欧州連合（EU）では180万人以上が死亡しています。欧州では全死亡の約45％、欧州連合では37％を占めています。

病歴と心電図に基づく現在の診断システムとトリアージシステムは、心血管疾患の適時診断には不十分であると見られています。その結果、一部の患者は誤診され、不適切な治療、ケア、検査が行われる可能性があります。また、診断が遅れた結果、早期に必要な治療が遅れて行われる（あるいは行われない）患者もいます。

したがって、心血管系疾患の早期診断の必要性が、心臓バイオマーカー検査の需要を促進しています。心臓バイオマーカーは、心血管疾患のタイムリーで正確な診断と管理において、また患者の予後を改善する上で非常に重要です。早期に治療を開始し、心筋障害を回復させるためには、黄金期における診断がもっとも重要です。心臓バイオマーカーもまた、トリアージの強力なツールです。

しかし、心筋壊死に対する感度と特異性の欠如は依然として続いており、より新しい特異的分子を探す必要があります。バイオマーカーの生化学に対する理解は限られており、サンプル収集と結果の取得における課題が、予測期間に心臓バイオマーカー検査市場の成長を抑制する可能性があります。

心臓バイオマーカー検査市場のセグメント分析

心臓バイオマーカー検査機器市場のバイオマーカータイプセグメントでは、心臓バイオマーカーのトロポニンカテゴリが最大の市場収益シェアを占めると予測されています。これは、その他のすべての心臓バイオマーカータイプの中で最良の心臓バイオマーカーと考えられていることに起因しています。このタンパク質は、圧倒的にもっとも一般的に使用されるバイオマーカーであり、もっとも感度が高いことが知られています。

トロポニンは心臓発作後すぐに血流に入り、その他のバイオマーカーに比べて長期にわたり血流にとどまります。トロポニンはトロポニンTとトロポニンIの2種類が測定されます。トロポニンIは心臓に特異性が高く、クレアチニンキナーゼ-MBよりも長く高さを維持すると考えられています。米国心臓協会（AHA）による最新のガイドラインでは、このバイオマーカーが心臓発作を発見するための最良のバイオマーカーであると言及されています。

さらに、心筋梗塞の心電図的証拠が不明確な患者もいます。そのような場合には、トロポニン心筋バイオマーカーが広く使用されています。

北米が心臓バイオマーカー検査市場全体を独占すると予測されます。

すべての地域の中で、北米が心臓バイオマーカー検査市場で最大のシェアを獲得する見込みです。心血管疾患の有病率の増加、優れた医療施設、主要市場企業のプレゼンス、研究開発活動への投資の増加などが、予測期間にわたって心臓バイオマーカー検査市場全体の成長を促進する主な影響要因になる見込みです。

当レポートでは、世界の心臓バイオマーカー検査市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 心臓バイオマーカー検査市場レポートのイントロダクション

第2章 心臓バイオマーカー検査市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 心臓バイオマーカー検査市場の主な要因の分析

  • 心臓バイオマーカー検査市場の促進要因
    • 心血管疾患の有病率の上昇
    • 疾患の早期診断の必要性の高まり
    • 成長する研究開発活動
    • 老年人口の増加
  • 心臓バイオマーカー検査市場の抑制要因と課題
    • 心臓バイオマーカーの生化学に関する限られた理解
    • サンプル収集と結果時間の課題
  • 心臓バイオマーカー検査市場の機会
    • 心臓バイオマーカーについての理解の向上
    • 心臓バイオマーカーを使用したポイントオブケア検査の増加

第5章 心臓バイオマーカー検査市場のポーターのファイブフォース分析

第6章 心臓バイオマーカー検査市場のレイアウト

  • 製品タイプ別
    • 機器
    • 試薬・キット
  • バイオマーカータイプ別
    • トロポニン
    • クレアチンキナーゼ-MB
    • ナトリウム利尿ペプチド
    • ミオグロビン
    • その他
  • 用途別
    • 急性冠症候群
    • うっ血性心不全
    • 心筋梗塞
  • エンドユーザー別
    • 病院
    • 病理学研究室
  • 地域別
    • 北米の心臓バイオマーカー検査の市場規模（2021年～2030年）
    • 欧州の心臓バイオマーカー検査の市場規模（2021年～2030年）
    • アジア太平洋の心臓バイオマーカー検査の市場規模（2021年～2030年）
    • その他の地域の心臓バイオマーカー検査の市場規模（2021年～2030年）

第7章 心臓バイオマーカー検査市場の企業と製品のプロファイル

  • Beckman Coulter, Inc.
  • Siemens Healthcare GmbH
  • Abbott
  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fischer Scientific Inc.
  • Bio-Rad Laboratories Inc.
  • Eurolyser Diagnostica GmbH
  • Diagnostic Automation/Cortez Diagnostics, Inc.
  • Randox Laboratories Ltd.
  • Tosoh Corporation
  • DIALAB GmbH
  • CardioGenics Holdings Inc.
  • Lepu Medical Technology (Beijing) Co. Ltd.
  • Biosynex

第8章 KOLの見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightのサービス内容

第11章 DelveInsightについて

第12章 免責事項と連絡先

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Cardiac Biomarker Testing Market in Global (2021-2030)
  • Table 3: Cardiac Biomarker Testing Market in Global by Product Type (2021-2030)
  • Table 4: Cardiac Biomarker Testing Market in Global by Biomarker Type (2021-2030)
  • Table 5: Cardiac Biomarker Testing Market in Global by Application (2021-2030)
  • Table 6: Cardiac Biomarker Testing Market in Global by End-User (2021-2030)
  • Table 7: Cardiac Biomarker Testing Market in Global by Geography (2021-2030)
  • Table 8: Cardiac Biomarker Testing Market in North America (2021-2030)
  • Table 9: Cardiac Biomarker Testing Market in the US (2021-2030)
  • Table 10: Cardiac Biomarker Testing Market in Canada (2021-2030)
  • Table 11: Cardiac Biomarker Testing Market in Mexico (2021-2030)
  • Table 12: Cardiac Biomarker Testing Market in Europe (2021-2030)
  • Table 13: Cardiac Biomarker Testing Market in France (2021-2030)
  • Table 14: Cardiac Biomarker Testing Market in Germany (2021-2030)
  • Table 15: Cardiac Biomarker Testing Market in the United Kingdom (2021-2030)
  • Table 16: Cardiac Biomarker Testing Market in Italy (2021-2030)
  • Table 17: Cardiac Biomarker Testing Market in Spain (2021-2030)
  • Table 18: Cardiac Biomarker Testing Market in Rest of Europe (2021-2030)
  • Table 19: Cardiac Biomarker Testing Market in Asia-Pacific (2021-2030)
  • Table 20: Cardiac Biomarker Testing Market in China (2021-2030)
  • Table 21: Cardiac Biomarker Testing Market in Japan (2021-2030)
  • Table 22: Cardiac Biomarker Testing Market in India (2021-2030)
  • Table 23: Cardiac Biomarker Testing Market in Australia (2021-2030)
  • Table 24: Cardiac Biomarker Testing Market in South Korea (2021-2030)
  • Table 25: Cardiac Biomarker Testing Market in Rest of Asia-Pacific (2021-2030)
  • Table 26: Cardiac Biomarker Testing Market in the Rest of the World (2021-2030)
  • Table 27: Cardiac Biomarker Testing Market in the Middle East (2021-2030)
  • Table 28: Cardiac Biomarker Testing Market in Africa (2021-2030)
  • Table 29: Cardiac Biomarker Testing Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Cardiac Biomarker Testing Market in Global (2021-2030)
  • Figure 3: Cardiac Biomarker Testing Market in Global by Product Type (2021-2030)
  • Figure 4: Cardiac Biomarker Testing Market in Global by Biomarker Type (2021-2030)
  • Figure 5: Cardiac Biomarker Testing Market in Global by Application (2021-2030)
  • Figure 6: Cardiac Biomarker Testing Market in Global by End-User (2021-2030)
  • Figure 7: Cardiac Biomarker Testing Market in Global by Geography (2021-2030)
  • Figure 8: Cardiac Biomarker Testing Market in North America (2021-2030)
  • Figure 9: Cardiac Biomarker Testing Market in the US (2021-2030)
  • Figure 10: Cardiac Biomarker Testing Market in Canada (2021-2030)
  • Figure 11: Cardiac Biomarker Testing Market in Mexico (2021-2030)
  • Figure 12: Cardiac Biomarker Testing Market in Europe (2021-2030)
  • Figure 13: Cardiac Biomarker Testing Market in France (2021-2030)
  • Figure 14: Cardiac Biomarker Testing Market in Germany (2021-2030)
  • Figure 15: Cardiac Biomarker Testing Market in the United Kingdom (2021-2030)
  • Figure 16: Cardiac Biomarker Testing Market in Italy (2021-2030)
  • Figure 17: Cardiac Biomarker Testing Market in Spain (2021-2030)
  • Figure 18: Cardiac Biomarker Testing Market in Rest of Europe (2021-2030)
  • Figure 19: Cardiac Biomarker Testing Market in Asia-Pacific (2021-2030)
  • Figure 20: Cardiac Biomarker Testing Market in China (2021-2030)
  • Figure 21: Cardiac Biomarker Testing Market in Japan (2021-2030)
  • Figure 22: Cardiac Biomarker Testing Market in India (2021-2030)
  • Figure 23: Cardiac Biomarker Testing Market in Australia (2021-2030)
  • Figure 24: Cardiac Biomarker Testing Market in South Korea (2021-2030)
  • Figure 25: Cardiac Biomarker Testing Market in Rest of Asia-Pacific (2021-2030)
  • Figure 26: Cardiac Biomarker Testing Market in the Rest of the World (2021-2030)
  • Figure 27: Cardiac Biomarker Testing Market in the Middle East (2021-2030)
  • Figure 28: Cardiac Biomarker Testing Market in Africa (2021-2030)
  • Figure 29: Cardiac Biomarker Testing Market in South America (2021-2030)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Marker Opportunities
  • Figure 33: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0072

Cardiac Biomarkers Testing Market By Product Type (Instruments and Reagents & Kits), Biomarker Type (Troponin, Creatine Kinase-Mb, B-Type Natriuretic Peptide, Myoglobin, and Others]), Application (Acute Coronary Syndrome, Congestive Heart Failure, Myocardial Infarction, and Others), End-User (Hospitals, Pathology Labs, and Others), and Geography is expected to grow at a steady CAGR forecast till 2030 owing to the rising geriatric population and increasing need for early disease diagnosis

The global cardiac biomarkers testing market was valued at USD 3.50 billion in 2023, growing at a CAGR of 7.77% during the forecast period from 2024 to 2030 to reach USD 5.48 billion by 2030. Factors such as the increasing prevalence of cardiovascular diseases, the growing need for early disease diagnosis, the rising aging population, and the advancement in research in identifying novel clinically-relevant cardiac biomarkers are stimulating the growth of the cardiac biomarker testing market positively.

Cardiac Biomarkers Testing Market Dynamics:

As per the data provided by the World Health Organization (2023), cardiovascular diseases (CVDs) are the leading cause of death across the globe, accounting for an estimated 17.9 million lives each year. Some of the CVDs include myocardial infarction, congestive heart failure, acute coronary syndrome, and other conditions. Furthermore, the same data by the WHO presented that over four out of five CVD deaths list strokes and heart attacks as the main cause and one-third of these deaths are said to occur prematurely in people below 70 years of age. The data also states that more than three-quarters of CVD deaths take place in low- and middle-income countries.

According to the data provided by the European Society for Cardiology (ESC) (2023), each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. They represent about 45% of all deaths in Europe and 37% in the European Union.

It has been observed that the current diagnostic and triage systems based on clinical history and electrocardiograms are insufficient for the timely diagnosis of cardiovascular diseases. They may result in some patients being misdiagnosed and being administered inappropriate treatment, care, and investigations. In some patients, the diagnosis is delayed resulting in the late administration (or no administration) of essential early treatment.

Therefore, the need for an early diagnosis of cardiovascular diseases is fuelling the demand for cardiac biomarker testing. Cardiac biomarkers are of great importance in the timely, accurate diagnosis and management of cardiovascular disease as well as in improving the prognosis of the disease for the patient. Diagnosis in the golden period is of utmost importance to institute therapy at the earliest and possibly reverse the myocardial damage. Cardiac biomarkers are also a powerful tool for triaging.

However, the lack of sensitivity and specificity to cardiac muscle necrosis continues to be the need to look for newer specific molecules, limited understanding of the biochemistry of the biomarkers, and challenges in sample collection and obtaining results may restrain the growth of the cardiac biomarker testing market during the forecast period.

Cardiac Biomarker Testing Market Segment Analysis:

Cardiac Biomarker Testing Market by Product Type (Instruments and Reagents & Kits), Biomarker Type (Troponin, Creatine Kinase-MB, Natriuretic Peptide, Myoglobin, and Others]), Application (Acute Coronary Syndrome, Congestive Heart Failure, Myocardial Infarction, and Others), End-User (Hospitals, Pathology Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the biomarker type segment of the cardiac biomarker testing devices market, the troponin category of cardiac biomarkers is predicted to account for the largest market revenue share. This can be ascribed to the fact that it is considered the best cardiac biomarker among all other cardiac biomarker types. This protein is by far the most commonly used biomarker and has the highest known sensitivity.

Troponin enters the bloodstream soon after a heart attack and remains in the bloodstream for a longer period as compared to other biomarkers. Two forms of troponin may be measured- troponin T and troponin I. Troponin I is considered to be highly specific to the heart and stays higher longer than creatinine kinase-MB. The latest guidelines by the American Heart Association (AHA) mention this biomarker to be the best biomarker for finding a heart attack.

Furthermore, in some patients the electrocardiographic evidence of myocardial infarction remains unclear; in such cases, troponin cardiac biomarkers are extensively used.

North America is expected to dominate the Overall Cardiac Biomarkers Testing Market:

Among all the regions, North America is expected to amass the largest share of the cardiac biomarker testing market. The growing prevalence of cardiovascular diseases, better healthcare facilities coupled with the presence of major market players as well as higher investment in the research and development activities in the region are predicted to be the major influencing factors in driving the overall growth of the cardiac biomarker testing market over the forecast period.

The Centers for Disease Control and Prevention (CDC) 2022, estimated that about 20.1 million adults aged 20 and older had Coronary artery disease (CAD) in the US, in 2020.

Also, the above-mentioned source further stated that in the United States, someone has a heart attack every 40 seconds. Every year, about 805,000 people in the United States have a heart attack. Out of these, 605,000 are a first heart attack, 200,000 happen to people who have already had a heart attack and about 1 in 5 heart attacks are silent-the damage is done, but the person is not aware of it.

As per the information provided by the Centers for Disease Control and Prevention (2023), some of the key risk factors associated with heart diseases are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.

Therefore, the presence of a large patient population suffering from heart disease is one of the major factors contributing to the North American cardiac biomarker testing market growth.

Moreover, the large presence of key market players as well as the launch of new products in the region as a reason for extensive R&D activities also provides favorable conditions for the growth of the North American cardiac biomarker testing market.

Cardiac Biomarkers Testing Devices Market Key Players:

Some of the key market players operating in the cardiac biomarker testing market include Beckman Coulter, Inc., Siemens Healthcare GmbH, Abbott, bioMerieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc., Bio-Rad Laboratories Inc, Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex and others.

Recent Developmental Activities in Cardiac Biomarkers Testing Market:

In April 2021, Roche announced the series of five new intended uses for two key cardiac biomarkers using the Elecsys® technology: high-sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP).

Key Takeaways from the Cardiac Biomarkers Testing Market Report Study

Market size analysis for cardiac biomarker testing market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global cardiac biomarker testing market.

Various opportunities available for the other competitor in the cardiac biomarker testing market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current cardiac biomarker testing market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for cardiac biomarker testing market growth in the coming future?

Target Audience who can be benefited from this Cardiac Biomarker Testing Market Report Study

Cardiac biomarkers testing devices products providers

Research organizations and consulting companies

Cardiac biomarkers testing devices -related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in cardiac biomarker testing

Various End-Users who want to know more about the cardiac biomarker testing market and the latest technological developments in the cardiac biomarker testing market.

Frequently Asked Questions for Cardiac Biomarker Testing Market:

1. What is a cardiac biomarker testing device?

Cardiac biomarkers are protein molecules that are released into the blood after heart damage or heart stress. These biomarkers act as a potential tool in the detection and diagnosis of various cardiovascular diseases.

2. What is the market for global cardiac biomarker testing?

The global cardiac biomarkers testing market was valued at USD 3.50 billion in 2023, growing at a CAGR of 7.77% during the forecast period from 2024 to 2030 to reach USD 5.48 billion by 2030.

3. What are the drivers for the global cardiac biomarker testing market?

The major drivers of the global cardiac biomarker testing market growth are the increasing prevalence of cardiovascular diseases, the growing need for early disease diagnosis, the rising aging population, and the advancement in research in identifying novel clinically-relevant cardiac biomarkers.

4. Who are the key players operating in the global cardiac biomarker testing market?

Some of the key market players operating in the cardiac biomarker testing market include Beckman Coulter, Inc, Siemens Healthcare GmbH, Abbott, bioMerieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc, Bio-Rad Laboratories Inc., Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex and others.

5. Which region has the highest share in the cardiac biomarker testing market?

North America is expected to dominate the overall cardiac biomarker testing market during the forecast period, 2024 to 2030. The accumulation of the highest revenue in the market can be ascribed to the rising prevalence of cardiovascular diseases, increasing focus on research and development activities, and the increasing collaborations between key market players in the region.

Table of Contents

1. Cardiac Biomarker Testing Market Report Introduction

2. Cardiac Biomarker Testing Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Cardiac Biomarker Testing Market Key Factors Analysis

  • 4.1. Cardiac Biomarker Testing Market Drivers
    • 4.1.1. Rising Prevalence of Cardiovascular Diseases
    • 4.1.2. Increasing Need for Early Disease Diagnosis
    • 4.1.3. Growing Research and Development Activities
    • 4.1.4. Rising Aging Population
  • 4.2. Cardiac Biomarker Testing Market Restraints and Challenges
    • 4.2.1. Limited Understanding of the Biochemistry of Cardiac Biomarkers
    • 4.2.2. Challenges in Sample Collection and Result Time
  • 4.3. Cardiac Biomarker Testing Market Opportunities
    • 4.3.1. Improvement in Understanding of Cardiac Biomarkers
    • 4.3.2. Increasing Point-of-Care Testing with Cardiac Biomarkers

5. Cardiac Biomarker Testing Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. Cardiac Biomarker Testing Market Layout

  • 6.1. By Product Type
    • 6.1.1. Instruments
    • 6.1.2. Reagents & Kits
  • 6.2. By Biomarkers Type
    • 6.2.1. Troponin
    • 6.2.2. Creatine Kinase-MB
    • 6.2.3. Natriuretic Peptide
    • 6.2.4. Myoglobin
    • 6.2.5. Others
  • 6.3. By Application
    • 6.3.1. Acute Coronary Syndrome
    • 6.3.2. Congestive Heart Failure
    • 6.3.3. Myocardial Infarction
    • 6.3.4. Others
  • 6.4. By End-User
    • 6.4.1. Hospitals
    • 6.4.2. Pathology Labs
    • 6.4.3. Others
  • 6.5. By Geography
    • 6.5.1. North America Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.1.1. United States Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.1.2. Canada Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.1.3. Mexico Cardiac Biomarker Testing Market Size in USD million (2021-2030)
    • 6.5.2. Europe Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.2.1. France Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.2.2. Germany Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.2.3. United Kingdom Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.2.4. Italy Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.2.5. Spain Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.2.6. Rest of Europe Cardiac Biomarker Testing Market Size in USD million (2021-2030)
    • 6.5.3. Asia-Pacific Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.3.1. China Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.3.2. Japan Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.3.3. India Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.3.4. Australia Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.3.5. South Korea Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.3.6. Rest of Asia-Pacific Cardiac Biomarker Testing Market Size in USD million (2021-2030)
    • 6.5.4. Rest of the World (RoW) Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.4.1. Middle East Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.4.2. Africa Cardiac Biomarker Testing Market Size in USD million (2021-2030)
      • 6.5.4.3. South America Cardiac Biomarker Testing Market Size in USD million (2021-2030)

7. Cardiac Biomarker Testing Market Company and Product Profiles

  • 7.1. Beckman Coulter, Inc.
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Siemens Healthcare GmbH
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Abbott
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. bioMerieux SA
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. F. Hoffmann-La Roche Ltd.
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Thermo Fischer Scientific Inc.
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. Bio-Rad Laboratories Inc.
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. Eurolyser Diagnostica GmbH
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Diagnostic Automation / Cortez Diagnostics, Inc.
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. Randox Laboratories Ltd.
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. Tosoh Corporation
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. DIALAB GmbH
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. CardioGenics Holdings Inc.
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. Lepu Medical Technology (Beijing) Co. Ltd.
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy
  • 7.15. Biosynex
    • 7.15.1. Company Overview
    • 7.15.2. Company Snapshot
    • 7.15.3. Financial Overview
    • 7.15.4. Product Listing
    • 7.15.5. Entropy

8. KOL Views

9. Project Approach

10. DelveInsight Capabilities

11. About DelveInsight

12. Disclaimer & Contact Us